What is Novartis AG - ADR Annual Revenue?

Novartis AG - ADR Annual Revenue rose 10.85%, in the last year to $51,722 M. Its sector's average revenue growth for the last fiscal year was 7.54%.

What is Novartis AG - ADR Annual Net Profit?

Novartis AG - ADR Annual Net Profit fell 19.59% in the last year to $11,941 M. Its sector's average net profit growth for the last fiscal year was -30.36%.

What is Novartis AG - ADR Price to Earning Ratio?

Novartis AG - ADR Price to Earning Ratio is 18.34, higher than its sector PE ratio of 3.22.

What is Novartis AG - ADR Stock Price?

Novartis AG - ADR Stock Price rose 17.49% and outperformed its sector by 10.16% in the past year.

What is Novartis AG - ADR Quarterly Revenue?

Novartis AG - ADR Quarterly Revenue rose 15.13% YoY to $13,558 M. Its sector's average revenue growth YoY for the quarter was 5.84%.

What is Novartis AG - ADR Quarterly Net profit?

Novartis AG - ADR Quarterly Net profit fell 66.77% YoY to $2,818 M. Its sector's average net profit growth YoY for the quarter was -48.37%.

What is Novartis AG - ADR Debt to Equity Ratio?

Novartis AG - ADR Debt to Equity Ratio of 0.71 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is Novartis AG - ADR Return on Equity(ROE)?

Novartis AG - ADR Return on Equity(ROE) for the last financial year was 26.33%, more than 20% in the last financial year, indicating an efficient use of shareholder's capital to generate profit.

What is Novartis AG - ADR Interest Coverage Ratio?

Novartis AG - ADR Interest Coverage Ratio is 14.56, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).

What is Novartis AG - ADR Institutional Holding?

Novartis AG - ADR Institutional Holding increased by 0.03% in the last quarter to 6.75.

How is the Novartis AG - ADR today?

The Novartis AG - ADR today is trading in the green, up by 1.17% at 110.86.

How has Novartis AG - ADR performed historically?

The Novartis AG - ADR is currently trading up 1.17% on an intraday basis in the past week the index rose 3.11%. The index has been up 13.67% in the past quarter and rose 17.49% in the past year. You can view this in the overview section.

Novartis AG - ADR XNYS: NVS

Novartis AG - ADR Live Share Price Today, Share Analysis and Chart

Name: Novartis AG - ADR: Is Infosys Ltd. worth buying?
Item: Novartis AG - ADR
Rating: 2.65065275
Author: Trendlyne DVM scores

Mid-range Performer

Download real time

110.86 1.28 (1.17%)

1.6M XNYS Volume

XNYS 17 Apr, 2025 5:30 PM (EDT)

Board Meeting

The next board meeting for Novartis AG - ADR is on 29 Apr 2025 for the purpose of Novartis AG First Quarter Earnings Result for 2025 See details

Novartis AG - ADR Key Metrics

My Metrics

Default

Market Capitalization High in industry Unavailable in chosen country	218,958.4
PE TTM High in industry Unavailable in chosen country	18.3
PEG TTM Negative PEG TTM Unavailable in chosen country	-0.9
Price to Book High in industry Unavailable in chosen country	5
Institutional holding current Qtr % Low in industry Unavailable in chosen country	6.7
Revenue Growth Qtr YoY % Below industry Median Unavailable in chosen country	15.1
Operating Revenue growth TTM % Below industry Median Unavailable in chosen country	10.8
Net Profit Qtr Growth YoY % Negative Net Profit Qtr Growth YoY % Unavailable in chosen country	-66.8
Net Profit TTM Growth % Negative Net Profit TTM Growth % Unavailable in chosen country	-19.6
Operating Profit Margin Qtr % High in industry Unavailable in chosen country	26
Operating Profit Margin TTM % High in industry Unavailable in chosen country	28.1
Piotroski Score High in industry Unavailable in chosen country	6
Rel Perf vs Sector quarter% Unavailable in chosen country	14.6
ROE Annual % High in industry Unavailable in chosen country	26.3
RoA Annual % High in industry Unavailable in chosen country	11.8

All financials are in USD Million and price data in USD

High Financial Strength

61.1 / 100

Mid Valuation

35.0 / 100

Technically Neutral

54.8 / 100

Mid-range Performer These stocks are with strong quality. Their reasonable financials and technical aspects successfully gather investor's interest. View Similar Embed DVM

112

1Yr Price target upside is 1%

12 analysts

Check Before You Buy

Check P/E Buy Sell Zone

Sell Zone

62.0 % into P/E buy sell zone

Strong upside potential

% time spent below current P/E

Gains already realized

Novartis AG - ADR Stock Price Analysis

Day Price Range 1.2% 1 Day return Unavailable in chosen country	110.9 (LTP) 109.5111.3 LowHigh
Week Price Range 3.1% 1 Week return Unavailable in chosen country	110.9 (LTP) 107.1111.3 LowHigh
Month Price Range -2.1% 1 Month return Unavailable in chosen country	110.9 (LTP) 97.7114.4 LowHigh
52 Week Price Range 17.5% 1 Year return Unavailable in chosen country	110.9 (LTP) 94.7120.9 LowHigh

View full Share Price History

Novartis AG - ADR Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Miss

Novartis AG - ADR's Revenue was lower than average estimate 3 times in past 3 years

EPS forecast

QUARTER
ANNUAL

Current EPS

5.9

Avg. Estimate

6.8

Low Estimate

6.4

High Estimate

7.1

Current EPS

Avg. Estimate

Hit

EPS is expected to grow by 15.4% in FY25

Consensus Recommendation

13 ANALYST Recommendations

HOLD

The consensus recommendation from 13 analysts for Novartis AG - ADR is HOLD

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Novartis AG - ADR Stock Analysis

Novartis AG - ADR stock analysis with key metrics, changes, and trends.

Novartis AG - ADR Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Revenue	$51,722 M	10.85%	positive	Annual Revenue rose 10.85%, in the last year to $51,722 M. Its sector's average revenue growth for the last fiscal year was 7.54%.
Annual Net Profit	$11,941 M	19.59%	negative	Annual Net Profit fell 19.59% in the last year to $11,941 M. Its sector's average net profit growth for the last fiscal year was -30.36%.
Price to Earning Ratio	18.34	-	negative	Price to Earning Ratio is 18.34, higher than its sector PE ratio of 3.22.
Stock Price	$110.86	17.49%	positive	Stock Price rose 17.49% and outperformed its sector by 10.16% in the past year.
Quarterly Revenue	$13,558 M	15.13%	positive	Quarterly Revenue rose 15.13% YoY to $13,558 M. Its sector's average revenue growth YoY for the quarter was 5.84%.
Quarterly Net profit	$2,818 M	66.77%	negative	Quarterly Net profit fell 66.77% YoY to $2,818 M. Its sector's average net profit growth YoY for the quarter was -48.37%.
Debt to Equity Ratio	0.71	-	positive	Debt to Equity Ratio of 0.71 is less than 1 and healthy. This implies that its assets are financed mainly through equity.
Return on Equity(ROE)	26.33 %	26.33%	positive	Return on Equity(ROE) for the last financial year was 26.33%, more than 20% in the last financial year, indicating an efficient use of shareholder's capital to generate profit.
Interest Coverage Ratio	14.56	-	positive	Interest Coverage Ratio is 14.56, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).
Institutional Holding	6.75 %	0.03%	positive	Institutional Holding increased by 0.03% in the last quarter to 6.75.

VIEW LESS

Loading data..

Novartis AG - ADR - Company Profile

What does Novartis AG - ADR do?

Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.

Year

Dr. Klaus Moosmayer, PhD

Chief Ethics, Risk and Compliance Officer

2024

413.78 K

2024

Gross Remuneration

Year

Novartis AG - ADR Live Share Price Today, Share Analysis and Chart

Novartis AG - ADR Key Metrics

Market Capitalization

PE TTM

PEG TTM

Rel Perf vs Sector quarter%

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

ROE Annual %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

RoA Annual %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Novartis AG - ADR Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Novartis AG - ADR Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Novartis AG - ADR's Revenue was lower than average estimate 3 times in past 3 years

EPS forecast

EPS is expected to grow by 15.4% in FY25

Consensus Recommendation

The consensus recommendation from 13 analysts for Novartis AG - ADR is HOLD

Novartis AG - ADR Stock Analysis

Novartis AG - ADR stock analysis with key metrics, changes, and trends.

Annual Revenue rose 10.85%, in the last year to $51,722 M. Its sector's average revenue growth for the last fiscal year was 7.54%.

Annual Net Profit fell 19.59% in the last year to $11,941 M. Its sector's average net profit growth for the last fiscal year was -30.36%.

Price to Earning Ratio is 18.34, higher than its sector PE ratio of 3.22.

Stock Price rose 17.49% and outperformed its sector by 10.16% in the past year.

Quarterly Revenue rose 15.13% YoY to $13,558 M. Its sector's average revenue growth YoY for the quarter was 5.84%.

Quarterly Net profit fell 66.77% YoY to $2,818 M. Its sector's average net profit growth YoY for the quarter was -48.37%.

Debt to Equity Ratio of 0.71 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE) for the last financial year was 26.33%, more than 20% in the last financial year, indicating an efficient use of shareholder's capital to generate profit.

Interest Coverage Ratio is 14.56, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).

Institutional Holding increased by 0.03% in the last quarter to 6.75.

Novartis AG - ADR - Company Profile

What does Novartis AG - ADR do?

Novartis AG - ADR Management structure

Dr. Vasant Narasimhan

Chief Executive Officer

Mr. Harry Kirsch

Chief Financial Officer

Dr. Patrick Horber, M.D.

President, International

Mr. Victor Bulto

President, US

Dr. Steffen Lang, PhD

President, Operations

Dr. Klaus Moosmayer, PhD

Chief Ethics, Risk and Compliance Officer

Novartis AG - ADR Board of directors

Mr. Joerg Reinhardt, PhD

Chairman of the Board

Mr. Simon E Moroney, D.Phil.

Vice Chairman of the Board